ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

3.44
-0.05
(-1.43%)
Cerrado 20 Noviembre 3:00PM
3.44
0.00
( 0.00% )
Pre Mercado: 6:00AM

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
3.44
Postura de Compra
3.33
Postura de Venta
3.60
Volume Operado de la Acción
7
0.00 Rango del Día 0.00
1.79 Rango de 52 semanas 4.725
Capitalización de Mercado [m]
Precio Anterior
3.44
Precio de Apertura
-
Última hora de negociación
05:49:01
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,154,510
Acciones en circulación
189,491,685
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-8.95
Beneficio por acción (BPA)
-0.38
turnover
18.14M
Beneficio neto
-72.85M

Acerca de Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Burnaby, British Columbia, Can
Fundado
-
Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was US$3.44. Over the last year, Arbutus Biopharma shares have traded in a share price range of US$ 1.79 to US$ 4.725.

Arbutus Biopharma currently has 189,491,685 shares in issue. The market capitalisation of Arbutus Biopharma is US$651.85 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.95.

ABUS Últimas noticias

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the...

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.26-7.027027027033.73.813.4210805113.56782011CS
4-0.61-15.06172839514.054.13.428116123.75720712CS
12-0.41-10.64935064943.854.7253.4211545104.03231299CS
260.3410.96774193553.14.7252.91510589733.74702206CS
521.6390.05524861881.814.7251.7910586693.21878598CS
1560.175.198776758413.276.51.6917521943.49313364CS
2601.92126.3157894741.5290.8821316593.71104499CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
US$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
US$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
US$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
US$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
US$ 0.9853
(25.41%)
5.59M

ABUS Discussion

Ver más
db7 db7 1 semana hace
nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944
👍️0
db7 db7 1 semana hace
2 days to AASLD...
👍️0
mick mick 4 semanas hace
👍️0
db7 db7 1 mes hace
2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data
👍️0
mick mick 2 meses hace
https://www.stockscores.com/charts/charts/?ticker=ABUS
👍️0
mick mick 2 meses hace
ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT
👍️0
db7 db7 3 meses hace
breaking out; dare i say 'someone' knows 'something'(?)
👍️0
db7 db7 3 meses hace
ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"
👍️0
db7 db7 3 meses hace
ABUS over $4
👍️0
Monksdream Monksdream 3 meses hace
ABUS under $4
👍️0
DewDiligence DewDiligence 4 meses hace
ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.
👍️0
Rockurstocks Rockurstocks 4 meses hace
Not for long! $ABUS$
👍️0
Monksdream Monksdream 4 meses hace
ABUS under $4
👍️0
mick mick 4 meses hace
ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT
👍️0
Monksdream Monksdream 4 meses hace
ABUS new 52/week high
👍️0
db7 db7 4 meses hace
👍️0
db7 db7 5 meses hace
https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt
👍️0
db7 db7 6 meses hace
New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852
👍️0
db7 db7 6 meses hace
Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf
👍️0
mick mick 6 meses hace
ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes
👍️0
db7 db7 6 meses hace
EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"
👍️0
db7 db7 6 meses hace
Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value
👍️0
db7 db7 6 meses hace
issue here, now, might be too many open $3 calls? will mm's hold her under....
👍️0
db7 db7 6 meses hace
mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price
👍️0
MWM MWM 6 meses hace
Nice!
👍️0
db7 db7 6 meses hace
https://www.businesswire.com/news/home/20240517970994/en/
👍️0
db7 db7 6 meses hace
from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."
👍️0
Monksdream Monksdream 7 meses hace
ABUS under $3
👍️0
mick mick 7 meses hace
TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:
👍️0
Monksdream Monksdream 8 meses hace
ABUS new 52 hi
👍️0
db7 db7 8 meses hace
looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june
👍️0
mick mick 8 meses hace
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 8 meses hace
ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890
👍️0
mick mick 8 meses hace
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 meses hace
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 meses hace
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
mick mick 8 meses hace
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM
👍️0
Paullee Paullee 8 meses hace
07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.
👍️0
MWM MWM 8 meses hace
Watching all 3 stocks. $ABUS is kind of moving...
👍️0
db7 db7 8 meses hace
was going to take all '3' to explode imo..
👍️0
MWM MWM 8 meses hace
Yes, I'm trying to read it myself
👍️0
db7 db7 8 meses hace
decision is out; looks like arbutus won '2' and moderna '1' .. please confirm
👍️0
db7 db7 8 meses hace
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 9 meses hace
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 9 meses hace
Handle on twitter is @DesertDweller93
👍️0
MWM MWM 9 meses hace
Great post!

What’s your handle on Twitter?
👍️0
Desert dweller Desert dweller 9 meses hace
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
👍️0
MWM MWM 9 meses hace
A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s
👍️0
db7 db7 9 meses hace
yes, quite the drop yesterday and today on mrna... g/l!
👍️0
MWM MWM 9 meses hace
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
👍️0